Format

Send to

Choose Destination
Dermatol Res Pract. 2014;2014:240856. doi: 10.1155/2014/240856. Epub 2014 Aug 21.

Narrow-Band Ultraviolet B versus Oral Minocycline in Treatment of Unstable Vitiligo: A Prospective Comparative Trial.

Author information

1
Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
2
Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Students' Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
3
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

BACKGROUND:

We have compared NB-UVB and oral minocycline in stabilizing vitiligo for the first time.

SUBJECTS AND METHODS:

42 patients were divided equally into two groups: the NB-UVB and minocycline groups. Phototherapy was administered twice a week on nonconsecutive days. In the minocycline group, patients were advised to take minocycline 100 mg once daily. The treatment period was 3 months. Vitiligo disease activity (VIDA) score was noted every 4 weeks for 12 months. Digital photographs were taken at baseline and monthly intervals.

RESULTS:

Before the therapy, disease activity was present in 100% of the patients, which was reduced to 23.8% and 66.1% by the end of therapy in the NB-UVB and minocycline groups retrospectively (P < 0.05). 16 of the 21 (76/1%) patients with unstable disease in the NB-UVB group achieved stability, whereas this was the case for only 7 of the 21 (33.3%) in the minocycline group (P < 0.001). The diameter changes were statistically significant at the end of treatment in the NB-UVB group compared to the minocycline group (P = 0.031). Side effects in both groups were mild.

CONCLUSION:

NB-UVB was statistically more advantageous than oral minocycline in unstable vitiligo in terms of efficacy and the resulting stability.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center